Amyotrophic lateral sclerosis (als)
Drug research and approvals for amyotrophic lateral sclerosis (als): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 174 studies of amyotrophic lateral sclerosis (als) are recruiting on ClinicalTrials.gov, Health Canada has authorized 57 drug trials for it since 2013, FDA has 8 approved and 134 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 174
- Trials authorized in Canada: 57
- FDA orphan approvals: 8
- EU medicines: 3
Recruiting Now
Newest start dates first, of 174 recruiting on ClinicalTrials.gov ↗- Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)NCT07521930 · Not applicable · Johns Hopkins University · starts Jan 1, 2027
- Brain-Computer Interface Communication Device for People With ALSNCT07871071 · Not applicable · Cognixion · starts Nov 15, 2026
- Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body MyositisNCT07823101 · Not reported · Johns Hopkins University · starts Nov 1, 2026
- An Early Feasibility Study of a Robotically Implanted Brain-Computer Interface for Neural Control of External Devices…NCT07929792 · Not applicable · Neuralink Corp · starts Nov 1, 2026
- A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)NCT07855211 · Phase 1 / Phase 2 · Biogen · starts Oct 7, 2026
- Register for Medical Data, Functional Scales, and Care Outcomes in ALS, SMA, and Other Motor System DisordersNCT07900672 · Not reported · Ambulanzpartner Soziotechnologie APST GmbH · starts Oct 1, 2026
- Developing New Ways to Detect Respiratory Impairment Early in ALSNCT07844590 · Not reported · Thomas Jefferson University · starts Sep 1, 2026
- Healey ALS MyMatch Common Screening ProtocolNCT07400393 · Not reported · Massachusetts General Hospital · starts Aug 31, 2026
- FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALSNCT07674667 · Phase 1 / Phase 2 · Trace Neuroscience, Inc. · starts Aug 20, 2026
- Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?NCT07454733 · Not applicable · Trustees of Dartmouth College · starts Aug 12, 2026
Trials Authorized in Canada
The 10 newest of 57; search them all in Canada trials| Apr 1, 2026 | A master protocol for open-label extension studies to evaluate the long term safety and tolerability of interventions in various stages of clinical development…LY4256984 | Eli Lilly | Ongoing |
| Jan 30, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine in participants with amyotrophic lateral…PRIDOPIDINE | PRILENIA THERAPEUTICS B.V. | Ongoing |
| Dec 19, 2025 | Phase 2, randomized, double-blind, placebo-controlled, multi-center, 24-week study with additional 24-week blinded active extension to evaluate the safety and…COYA 302 | COYA THERAPEUTICS | Ongoing |
| Oct 8, 2025 | A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and…USNOFLAST (ZYIL1) | ZYDUS THERAPEUTICS INC. | Ongoing |
| Oct 16, 2024 | Targeting neuroinflammation with enhanced delivery of intravenous immunoglobulin to the motor cortex using next generation dome helmet focused ultrasound in…PRIVIGEN (IMMUNOGLOBULIN (HUMAN)) / DEFINITY (PERFLUTREN) | SUNNYBROOK RESEARCH INSTITUTE | Ongoing |
| Oct 2, 2024 | A phase 2, randomized, double-blind, placebo-controlled parallel group study of vhb937 in amyotrophic lateral sclerosis (als) over 40 weeks followed by an…VHB937 | Novartis Pharmaceuticals Corporation | Closed |
| Jun 26, 2024 | A phase 2a, double-blinded, randomized, placebo-controlled, and active-treatment extension study to assess the safety, tolerability, efficacy,…ARGX-119 | argenx US, Inc. | Closed |
| Apr 5, 2024 | First in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered…ALN-SOD | Regeneron | Ongoing |
| Nov 16, 2023 | A phase 1, randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of single ascending…PROSETIN (COL-001) | PROJENX, INC. | Ongoing |
| Oct 13, 2023 | A phase 1b, open-label, multiple ascending dose, multicenter study of vrg50635 in participants with sporadic and familial amyotrophic lateral sclerosis…VRG50635 | VERGE GENOMICS | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 142| Apr 25, 2023 | Qalsodytreatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene | Biogen Inc. | Approved |
| Sep 29, 2022 | RelyvrioTreatment of amyotrophic lateral sclerosis (ALS) in adults | Amylyx Pharmaceuticals, Inc. | Approved |
| May 12, 2022 | Radicava ORSTreatment of amyotrophic lateral sclerosis (ALS) | Tanabe Pharma America Inc. | Approved |
| Dec 13, 2019 | TiglutikTIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS). | Italfarmaco SpA | Approved |
| Nov 22, 2019 | EXSERVANEXSERVAN is indicated for the treatment of amyotrophic lateral sclerosis (ALS). | Aquestive Therapeutics | Approved |
| Sep 5, 2018 | TiglutikTIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS). | Italfarmaco SpA | Approved |
| May 5, 2017 | RadicavaTreatment of amyotrophic lateral sclerosis (ALS) | Tanabe Pharma America Inc. | Approved |
| Dec 12, 1995 | RilutekTreatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy. | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Approved |
| Sep 8, 2026 | stem cell-derived protein complex derived from the…treatment of amyotrophic lateral sclerosis | Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. | Designated |
| May 29, 2026 | mitogen-activated protein kinase (MAPK)/extracellular…treatment of amyotrophic lateral sclerosis | Pasithea Therapeutics Corp. | Designated |
| Apr 6, 2026 | a selective transactive response DNA-binding protein 43…treatment of amyotrophic lateral sclerosis | Talengen America Limited | Designated |
| Mar 2, 2026 | meloxicamtreatment of amyotrophic lateral sclerosis | AniMusCure Inc. | Designated |
| Feb 27, 2026 | alpha-lipoic acidtreatment of amyotrophic lateral sclerosis | Wenling City Innovation Biotechnology Co., Ltd. | Designated |
| Feb 23, 2026 | L-methionine-S,R-sulfoximinetreatment of amyotrophic lateral sclerosis | William S. Brusilow | Designated |
| Oct 17, 2025 | allogeneic, cord blood-derived T regulatory cells that…treatment of amyotrophic lateral sclerosis | Cellenkos Inc | Designated |
Medicines Authorised in the EU
Newest first| May 29, 2024 | Qalsodytofersen · orphan | Biogen Netherlands B.V. | EMA ↗ |
| May 7, 2012 | Riluzole Zentivariluzole | Zentiva k.s. | EMA ↗ |
| Jun 10, 1996 | Rilutekriluzole | Sanofi Winthrop Industrie | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA